Revised forecast
Fiscal year ending June 2026 · Full yearPrevious forecast published Published on 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Progress on orders in the Healthcare Support Business exceeded plan, improvement in the profitability of the Health Supplement Business from a lower cost ratio exceeded expectations, development activities were brought in-house, management resources were optimally allocated, and expenses associated with the cessation of the business activities of ビービーラボラトリーズ were lower than expected, among other factors.
| Item | Details |
|---|---|
| Net Sales | 3,860 Millions of yen → 3,871 Millions of yen（+0.3%） |
| Operating profit | 200 Millions of yen → 275 Millions of yen（+37.8%） |
| Ordinary income | 215 Millions of yen → 287 Millions of yen（+33.9%） |
| Profit attributable to owners of the parent | 120 Millions of yen → 212 Millions of yen（+76.9%） |
| Net income per share | 4.59 yen → 8.12 yen |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | Published on 13 May 2026 |
| Previous-period results | Revenue: ¥4,848 million; operating loss: ¥137 million; ordinary loss: ¥129 million; net loss attributable to owners of the parent: ¥210 million; net loss per share: ¥8.05 |
| Reason for the revision | Progress on orders in the Healthcare Support Business exceeded plan, improvement in the profitability of the Health Supplement Business from a lower cost ratio exceeded expectations, development activities were brought in-house, management resources were optimally allocated, and expenses associated with the cessation of the business activities of ビービーラボラトリーズ were lower than expected, among other factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although fourth-quarter revenue was generally in line with the previous forecast, profit at each level exceeded expectations due to factors including progress on orders in the Healthcare Support Business exceeding plan, greater-than-expected improvement in the profitability of the Health Supplement Business from a lower cost ratio, improved development efficiency through the in-house execution of development activities, optimal allocation of management resources with emphasis on investment effectiveness, and lower-than-expected expenses associated with the cessation of the business activities of 株式会社ビービーラボラトリーズ.